# Oral Fosamprenavir + Sodium Alginate for GERD

> **NCT06704100** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 60 (estimated)

## Conditions studied

- Refractory Gastroesophageal Reflux Disease
- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Fosamprenavir Calcium & Sodium Alginate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06704100
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704100, "Oral Fosamprenavir + Sodium Alginate for GERD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06704100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*